Josefina Perez Maturo

Dr. Josefina Perez Maturo

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
VSValeria Salinas
Valeria Salinas
NMNerina Martínez
Nerina Martínez
JMJosefina Perez Maturo
Josefina Perez Maturo
SRSergio A. Rodriguez-Quiroga
Sergio A. Rodriguez-Quiroga
LZLucia Zavala
Lucia Zavala
PVPatricia Vega
Patricia Vega

26 March 2019 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
JMJosefina Perez Maturo
Josefina Perez Maturo
PVPatricia Vega
Patricia Vega
NMNancy Medina
Nancy Medina
VSValeria Salinas
Valeria Salinas
MPMicaela Pauni
Micaela Pauni
MKMarcelo Kauffman
Marcelo Kauffman

21 June 2020 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
PDF file
JMJosefina Perez Maturo
Josefina Perez Maturo
MCMarcela Gonzalez Cid
Marcela Gonzalez Cid
LZLucia Zavala
Lucia Zavala
SQSergio Rodriguez Quiroga
Sergio Rodriguez Quiroga
MKMarcelo Kauffman
Marcelo Kauffman

23 November 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
Luca MarsiliLuca Marsili
Luca Marsili
KDKevin Duque
Kevin Duque
JAJesus Abanto
Jesus Abanto
NPNathaly Olga Chinchihualpa Paredes
Nathaly Olga Chinchihualpa Paredes
ADAndrew Duker
Andrew Duker
MKMarcelo Kauffman
Marcelo Kauffman
Background: Rare movement disorders often have a genetic etiology. New technological advances have increased the odds of achieving genetic diagnoses: next-generation sequencing (NGS) (whole-exome sequencing—WES; whole-genome sequencing—WGS) and long-read sequencing (LRS). In 2017, we launched a WES program for patients with rare movement disorders of suspected genetic etiology. We aim to describe the accumulated experience of a modern movement disorder genetic clinic, highlighting how different available genetic tests might be prioritized according to the clinical phenotype and pattern of inheritance. Methods: Participants were studied through WES analysis. Descriptive statistics, including the mean, standard deviation, counts, and percentages, were used to summarize demographic and clinical characteristics in all subjects and with each type of result [pathogenic or likely pathogenic, variants of uncertain significance (VUS), negative]. Results: We studied 88 patients (93.2% Caucasian, 5.72% African American, and 1.08% Hispanic or Latino). After excluding six family members from four index participants, the diagnostic yield of WES reached 27% (22/82 probands). The age at onset was significantly lower in patients with pathogenic/likely pathogenic variants. The most common clinical phenotypes were ataxia and parkinsonism. Dystonia, ataxia, leukoencephalopathy, and parkinsonism were associated with most genetic diagnoses. Conclusions: We propose a comprehensive protocol with decision tree testing for WGS and LRS, a return of results, and a re-analysis of inconclusive genetic data to increase the diagnostic yield of patients with rare neurogenetic disorders.

23 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JMJosefina Perez Maturo
Josefina Perez Maturo
LZLucia J Zavala
Lucia J Zavala
PVPatricia Vega
Patricia Vega
DGD González-Morón
D González-Morón
NMNancy Medina
Nancy Medina
MKMarcelo Andres Kauffman
Marcelo Andres Kauffman
Ataxias is one of the most frequent complaints in Neurogenetics units worldwide. Currently, more than 50 subtypes of spinocerebellar ataxias and more than 60 recessive ataxias are recognized. We conducted an 11-year prospective, observational, analytical study in order to estimate the frequency of pediatric and adult genetic ataxias in Argentina, to describe the phenotypes of this cohort and evaluate the diagnostic yield of the algorithm used in our unit. We included 334 ataxic patients. Our diagnostic approach was successful in one third of the cohort. A final molecular diagnosis was reached in 113 subjects. This rate is significantly higher in the subgroup of patients with a positive family history, where the diagnostic yield increased to 55%. The most prevalent dominant and recessive ataxias in Argentina were SCA-2 (36% of dominant ataxias) and FA (62% of recessive ataxias), respectively. Next generation sequencing based assays were diagnostic in the 65% of the patients requiring these tests. These results provide relevant epidemiological information, bringing a comprehensive knowledge of the most prevalent subtypes of genetic ataxias and their phenotypes in our territory and laying the groundwork for rationally implementing genetic diagnostic programs for these disorders in our country.